{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:12:24Z","timestamp":1763017944566,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002130","name":"Heineman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bbmt.2018.11.015","type":"journal-article","created":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T02:20:25Z","timestamp":1543026025000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Manisha","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Foureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myra","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adina S.","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nury M.","family":"Steuerwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-2252","authenticated-orcid":false,"given":"Lawrence J.","family":"Druhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed","family":"Friend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Symanowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda R.","family":"Avalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Copelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.11.015_bib0001","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0002","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/10428199809059231","article-title":"The expression of T cell related costimulatory molecules in multiple myeloma","volume":"31","author":"Brown","year":"1998","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0004","doi-asserted-by":"crossref","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0005","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0006","doi-asserted-by":"crossref","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of NK cells and disruption of PD-L1\/PD-1 axis: two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0008","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0009","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0010","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cyto.a.22033","article-title":"OMIP-007: phenotypic analysis of human natural killer cells","volume":"81","author":"Eller","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0012","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cyto.a.22269","article-title":"OMIP-017: human CD4(+) helper T-cell subsets including follicular helper cells","volume":"83","author":"Mahnke","year":"2013","journal-title":"Cytometry A"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0013","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cyto.a.22326","article-title":"OMIP-019: quantification of human gammadeltaT-cells, iNKT-cells, and hematopoietic precursors","volume":"83","author":"Mahnke","year":"2013","journal-title":"Cytometry A"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0014","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3389\/fimmu.2015.00583","article-title":"NK cell subgroups, phenotype, and functions after autologous stem cell transplantation","volume":"6","author":"Jacobs","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0015","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0017","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/bmt.2017.29","article-title":"Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication","volume":"52","author":"Arteche-Lopez","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0018","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3389\/fimmu.2018.01415","article-title":"NKG2A expression is not per se detrimental for the anti-multiple myeloma activity of activated natural killer cells in an in vitro system mimicking the tumor microenvironment","volume":"9","author":"Mahaweni","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0019","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0020","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0021","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00262-018-2140-1","article-title":"Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions","volume":"67","author":"Mahaweni","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0022","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/eji.200526177","article-title":"Regulation of gammadelta T cell survival by soluble HLA-I: involvement of CD8 and activating killer Ig-like receptors","volume":"35","author":"Poggi","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0023","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.4049\/jimmunol.160.11.5239","article-title":"Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL","volume":"160","author":"Bakker","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.bbmt.2018.11.015_bib0025","doi-asserted-by":"crossref","first-page":"20476","DOI":"10.18632\/oncotarget.24944","article-title":"Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation","volume":"9","author":"Fostier","year":"2018","journal-title":"Oncotarget"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118307481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118307481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:06:48Z","timestamp":1761059208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118307481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1083879118307481"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.11.015","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}